Next generation sequencing (NGS) of amplicons larger than 1000?bp simplified and accelerated a process of characterization of patient-specific BCR-ABL1 genomic fusions.     ///    " In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for the development of personalized medicine approach for minimal residual disease monitoring at the DNA level. "    ///    Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.. 